Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, raising approximately $1.5 million, with additional potential proceeds from unregistered warrants [1][3] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][9] - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [9] Offering Details - The registered direct offering was priced at-the-market under Nasdaq rules, and the unregistered warrants were issued concurrently, allowing for the purchase of an equal number of shares at the same exercise price [1][3] - The gross proceeds from the offering were approximately $1.5 million before fees and expenses, with the potential for an additional $1.5 million if the unregistered warrants are fully exercised [3] Regulatory Compliance - The shares offered in the registered direct offering were made under a "shelf" registration statement filed with the SEC, and a final prospectus supplement was filed with the SEC [4] - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [5]
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules